Q1 Earnings Estimate for CorMedix Issued By HC Wainwright

CorMedix Inc (NASDAQ:CRMD) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for CorMedix in a research note issued to investors on Friday, January 23rd. HC Wainwright analyst B. Folkes expects that the company will post earnings per share of $0.73 for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2030 earnings at $2.47 EPS.

Other equities analysts also recently issued research reports about the stock. D Boral Capital raised shares of CorMedix from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of CorMedix in a research note on Thursday, January 8th. Truist Financial set a $16.00 price objective on CorMedix in a report on Thursday, January 8th. Royal Bank Of Canada set a $13.00 target price on CorMedix and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Finally, Wall Street Zen lowered CorMedix from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $15.86.

CorMedix Price Performance

CorMedix stock opened at $7.75 on Monday. The stock has a market capitalization of $610.62 million, a P/E ratio of 3.76 and a beta of 1.36. CorMedix has a 12-month low of $5.60 and a 12-month high of $17.43. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.94 and a quick ratio of 1.73. The firm’s 50-day moving average is $10.05 and its two-hundred day moving average is $11.17.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The business had revenue of $104.28 million for the quarter, compared to analyst estimates of $65.63 million. During the same quarter last year, the company earned ($0.05) earnings per share. The business’s revenue for the quarter was up 810.2% compared to the same quarter last year.

Insider Activity at CorMedix

In other news, Director Steven W. Lefkowitz sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $11.88, for a total value of $475,200.00. Following the sale, the director directly owned 80,498 shares of the company’s stock, valued at approximately $956,316.24. The trade was a 33.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan W. Dunton sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total transaction of $260,000.00. Following the completion of the transaction, the director owned 40,250 shares in the company, valued at approximately $523,250. This represents a 33.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 90,000 shares of company stock worth $1,095,200. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On CorMedix

Institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP increased its position in shares of CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock valued at $40,397,000 after purchasing an additional 893,518 shares during the last quarter. Deerfield Management Company L.P. acquired a new position in shares of CorMedix during the 3rd quarter worth about $38,656,000. Geode Capital Management LLC increased its holdings in shares of CorMedix by 11.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,596,322 shares of the company’s stock valued at $19,669,000 after acquiring an additional 163,403 shares during the last quarter. Alyeska Investment Group L.P. raised its position in shares of CorMedix by 68.4% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,262,979 shares of the company’s stock worth $14,688,000 after acquiring an additional 512,979 shares in the last quarter. Finally, UBS Group AG boosted its holdings in CorMedix by 295.3% in the third quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after purchasing an additional 814,964 shares in the last quarter. Hedge funds and other institutional investors own 34.18% of the company’s stock.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.